CV Science

Mario Rienzo MD PhD Anesthesia and Critical Care

Course and current status

1. Education

• Doctoral degree

Paris Est – Créteil Val de Marne University (UPEC) - Philosophy Doctor Degree (PhD) in "Life and Health Science" (2008-2013) Thesis Defense: "Physio-pathological and pharmacological characterisation of a pig model with diastolic dysfunction and preserved ejection fraction" (INSERM U955, Equipe 03, Pr A. Berdeaux, Pr B. Ghaleh, Créteil).

• Courses and degrees

a. Paris V and VII University (Paris Descartes and Diderot) - Master 2 Degree in Life and Health Sciences, specialty “Cardiovascular-Haemostasis-Respiration Physiopathology” (2007-2008). Dissertation: "P947-targeted magnetic resonance molecular imaging of the aortic atheroma in rabbits with hypercholesterolemia undergoing an aortic double abrasion: effects of treatment by statins and LTB-RII receptor inhibitor".

b. University of Bari Medical School - Specialty Graduation in Anaesthesiology and Intensive Care (1999-2003). Dissertation: "Volemic expansion evaluation by aortic blood flow in patients with septic shock and spontaneous breathing activity".

c. University of Bari Medical School - Medical Doctor Graduation in Haematology (1992-98). Dissertation: "High dose chemotherapy and autologous peripheral hematopoietic stem cell grafting for patients with poor prognosis Hodgkin Disease in partial remission".

• University Diplomas

a. Paris V University (Paris Descartes) - Diploma in "Metabolic Disorders in Critically Ill Patients" (2018)

b. Bordeaux University II – Victor Segalen - Diploma in "Surgical Intensive Care and Anaesthesiology for Congenital Heart Diseases" (2016)

c. Paris Est – Créteil Val de Marne University (UPEC) - Inter-University Diploma in "Echo-cardiography" (2011)

d. Paris VII University (CHU Bichat – Claude Bernard) - Diploma in "Intensive Care for Infectious Diseases" (2006)

2. Professional Appointments

Anaesthesia and Intensive Care Department, Foch Hospital, Suresnes, France - Specialty Registrar in Cardiac post-surgical Intensive Care - 10.2003-04.2004

Polyvalent Intensive Care Department, Molinette Hospital, Turin - Specialty Registrar in Polyvalent Intensive Care - 02.2004-10.2004

Anaesthesia and Intensive Care Department, Pitié - Salpetrière Teaching Hospital, Paris, France - Specialty Registrar in Vascular Surgery Anaesthesia - 11.2004-10.2005 

Anaesthesia and Intensive Care Department, Henri Mondor Teaching Hospital, Creteil, France - Consultant in Cardiovascular Anaesthesia and Intensive Care Unit - 11.2005-06.2007

Intensive Care Department, Private Hospital Jacques Cartier, Massy, France - Part-time Consultant in Polyvalent Intensive Care Unit - 07.2007-12.2014

Anaesthesia Department, Troyes General Hospital, France - Part-time Consultant in Anaesthesiology - 07.2011-12.2012 

Anaesthesia and Intensive Care Department, H.E.G.P. Teaching Hospital, Paris, France - Part-time Consultant in Anaesthesiology - 01.2012-12.2012

Anaesthesia and Intensive Care Department, H.E.G.P. Teaching Hospital, Paris, France - Consultant in Cardiovascular Anaesthesia and Intensive Care Unit - 01.2013-11.2016; 10.2017-01.2018

Anaesthesia and Intensive Care Department, Bordeaux Teaching Hospital, Bordeaux, France - Consultant in Cardiovascular Anaesthesia and Intensive Care Unit - 12.2016-09.2017 

Anaesthesia Department, Institut Mutualiste Montsouris, Paris, France - Part-time Consultant in Anaesthesiology - 02.2018-05.2018 

Anaesthesia Department, Groupe Hospitalier Diaconesse – Croix Saint Simon, Paris, France - Part-time Consultant in Anaesthesiology - 02.2018-05.2018

Anaesthesia Department, Marie Lannelongue Hospital, Le Plessis Robinson, France - Consultant in Cardiothoracic and Vascular Anaesthesia - 06.2018-12.2019 

Pediatric Cardiac Surgery Department, Marie Lannelongue Hospital, Le Plessis Robinson, France - Consultant in Anaesthesiology and Critical Care - 01.2020-present

Scientific summary

Five to 10% of patients presenting with acute myocardial infarction develop cardiogenic shock. Despite the early myocardial revascularization, optimal pharmacological treatment and the use of short-term mechanical circulatory support, the mortality of cardiogenic shock complicating acute myocardial infarction remains abnormally high. Insights into cardiogenic shock’s pathophysiology remain crucial to the development of new therapeutic approaches. In this context, large animal models may provide a heuristic methodology to test pathophysiological hypotheses and thus new therapies. Our group developed a stable and reproductible closed chest sheep’s model of severe cardiogenic shock due to myocardial infarction. Percutaneous closed-chest models present the advantage to profoundly limit the huge trauma of thoracotomy, thus respecting cardiac and whole-body physiology and favouring recovery. Consequently, our model presents a high rate of survival after the induction of CS. Our experimental set-up could lead to a better understanding of mechanical interaction between short-term mechanical circulatory support and an acutely failing ventricle. The potential usefulness or harmfulness of vasoactive and inotropic drugs in patients assisted with those devices might also be explored in this model. Moreover, the impact of ventricular support on early remodelling of non-ischemic territory could be more fully investigated.